• Featured Product
  • KD/KO验证

LATS2-Specific Polyclonal antibody

LATS2-Specific Polyclonal Antibody for WB, IHC, IF/ICC, IP, ELISA
Cat No. 20276-1-AP

产品说明书

宿主/亚型

Rabbit / IgG

种属反应性

human, mouse

应用

WB, IHC, IF/ICC, IP, ELISA and More (2)

LATS2, Serine/threonine-protein kinase kpm, LATS 2, KPM, EC:2.7.11.1

缓冲液配方:  PBS and Azide
PBS and Azide
偶联物:  Unconjugated
Unconjugated
规格: 

-/ -


经过测试的应用

Positive WB detected inHEK-293 cells, human heart tissue
Positive IP detected inHEK-293 cells
Positive IHC detected inhuman liver cancer tissue, human colon tissue, mouse skeletal muscle tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
Positive IF/ICC detected inHepG2 cells
Planning an IHC experiment? We recommend our IHCeasy LATS2 Ready-To-Use IHC Kit. LATS2 primary antibody included.

推荐稀释比

应用推荐稀释比
Western Blot (WB)WB : 1:1000-1:8000
Immunoprecipitation (IP)IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
Immunohistochemistry (IHC)IHC : 1:50-1:500
Immunofluorescence (IF)/ICCIF/ICC : 1:20-1:200
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

产品信息

20276-1-AP targets LATS2-Specific in WB, IHC, IF/ICC, IP, CoIP, ELISA applications and shows reactivity with human, mouse samples.

经测试应用 WB, IHC, IF/ICC, IP, ELISA Application Description
文献引用应用WB, IHC, IF, IP, CoIP
经测试反应性 human, mouse
文献引用反应性human, mouse
免疫原 Peptide 种属同源性预测
宿主/亚型 Rabbit / IgG
抗体类别 Polyclonal
产品类型 Antibody
全称 LATS, large tumor suppressor, homolog 2 (Drosophila)
别名 LATS2, Serine/threonine-protein kinase kpm, LATS 2, KPM, EC:2.7.11.1
计算分子量 120 kDa
观测分子量130-150 kDa
GenBank蛋白编号NM_014572
基因名称 LATS2
Gene ID (NCBI) 26524
RRIDAB_10697657
偶联类型 Unconjugated
形式 Liquid
纯化方式Antigen affinity purification
UNIPROT IDQ9NRM7
储存缓冲液 PBS with 0.02% sodium azide and 50% glycerol , pH 7.3
储存条件Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.

背景介绍

LATS2, also named as KPM, belongs to the protein kinase superfamily and AGC Ser/Thr protein kinase family. LATS2 is a tumor suppressor which plays a critical role in centrosome duplication, maintenance of mitotic fidelity and genomic stability. It negatively regulates G1/S transition by down-regulating cyclin E/CDK2 kinase activity. It is a negative regulator of the androgen receptor. LATS2 has a calculated molecular mass of 120 kDa and an apparent molecular mass of 150 kDa (PMID: 10871863). The antibody is specific to LATS2.

实验方案

Product Specific Protocols
WB protocol for LATS2-Specific antibody 20276-1-APDownload protocol
IHC protocol for LATS2-Specific antibody 20276-1-APDownload protocol
IF protocol for LATS2-Specific antibody 20276-1-APDownload protocol
IP protocol for LATS2-Specific antibody 20276-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols

发表文章

SpeciesApplicationTitle
humanWB

Mol Cancer

Co-transcriptional R-loops-mediated epigenetic regulation drives growth retardation and docetaxel chemosensitivity enhancement in advanced prostate cancer

Authors - Yufan Ying
mouseWB

Cell Metab

Cholesterol Stabilizes TAZ in Hepatocytes to Promote Experimental Non-alcoholic Steatohepatitis.

Authors - Xiaobo Wang
  • KD Validated
humanWB

Cell Death Differ

The Hippo signaling component LATS2 enhances innate immunity to inhibit HIV-1 infection through PQBP1-cGAS pathway.

Authors - Tian-Sheng He
  • KO Validated
humanWB, CoIP

Clin Transl Med

Tumor-derived exosomal miR-19b-3p facilitates M2 macrophage polarization and exosomal LINC00273 secretion to promote lung adenocarcinoma metastasis via Hippo pathway.

Authors - Jing Chen
humanWB,IHC

Oxid Med Cell Longev

miR-25 Promotes Cell Proliferation, Migration, and Invasion of Non-Small-Cell Lung Cancer by Targeting the LATS2/YAP Signaling Pathway.

Authors - Tangwei Wu
humanWB

Oncogene

TRIB3 confers radiotherapy resistance in esophageal squamous cell carcinoma by stabilizing TAZ.

Authors - Sha Zhou
Loading...